{"entity":{"id":"nct05700084","kind":"trial","name":"Phase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Capecitabine in advanced solid tumours, run by Beijing Biostar Pharmaceuticals Co., Ltd., active and no longer recruiting.","summary":"Phase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05700084 by Beijing Biostar Pharmaceuticals Co., Ltd., with 84 participants enrolled, started 2023-06-09 and due to reach its primary completion in 2025-10-08. Interventions recorded: Utidelone Capsule (Part 1), Drug A Utidelone Capsule (Part 2: Group A-B), Drug A Utidelone Capsule (Part 2: Group B-A), Drug B Utidelone Injection (Part 2: Group A-B), Drug B Utidelone Injection (Part 2: Group B-A) and Capecitabine.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05700084","url":"https://clinicaltrials.gov/study/NCT05700084"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["capecitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05700084","phase":"1/2","setting":"Phase I-II Clinical Trial on Tolerability and Bioavailability of Utidelone Capsule in Patients With Advanced Solid Tumors","sponsor":"Beijing Biostar Pharmaceuticals Co., Ltd.","enrolled":84,"outcomes":[]},"route":"/trials/nct05700084/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"}]}}